GleamWall
中文EN

SGHT Sight Sciences, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1531177 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY16.2%
TTM net income YoY38.4%
TTM EPS YoY42.2%
Revenue 3-yr CAGR2.2%
Net income 3-yr CAGR—

Margins

Gross margin87.7%
Operating margin-29.5%
Net margin-32.1%
FCF margin-19.1%
EBITDA margin-29.1%

Returns

ROE-50.1%
ROA-25.7%
ROIC (approx.)-166.6%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets53.2%
Debt / equity0.83x
Current ratio5.04x
Interest coverage-5.06x

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue-0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$24.92M$23.39M$19.70M$20.39M$19.91M$19.56M$17.51M$19.07M
Cost of revenue$3.50M$2.01M$2.72M$2.60M$2.71M$2.98M$2.41M$2.51M
Gross profit$21.42M$21.37M$16.98M$17.79M$17.20M$16.59M$15.09M$16.56M
R&D expense$2.71M$2.51M$2.55M$2.44M$3.35M$4.39M$4.43M$4.29M
SG&A expense$24.84M$22.75M$26.84M$19.02M$21.75M$23.87M$24.52M$24.20M
Operating income-$6.13M-$3.89M-$12.41M-$3.67M-$7.91M-$11.67M-$13.86M-$11.93M
Interest expense$1.31M$1.29M$1.27M$1.29M$1.31M$1.28M$1.26M$1.16M
Pretax income-$6.80M-$4.42M-$12.97M-$4.15M-$8.25M-$11.90M-$14.11M-$11.81M
Income tax$11,000$28,000$11,000$8,000-$79,000$40,000$41,000$38,000
Net income-$6.81M-$4.45M-$12.98M-$4.16M-$8.17M-$11.94M-$14.15M-$11.85M
EBITDA-$6.03M-$3.79M-$12.31M-$3.56M-$7.80M-$11.57M-$13.71M-$11.75M
EPS (basic)-0.12-0.08-0.24—-0.16-0.23-0.28—
EPS (diluted)-0.12-0.08-0.24—-0.16-0.23-0.28—
Weighted avg. shares (diluted)55.13M54.51M53.94M—52.38M51.82M51.29M—
Balance sheet
Cash & equivalents$77.40M$79.75M$84.96M$91.97M$92.37M$101.50M$108.77M$120.36M
Receivables$13.38M$11.39M$10.60M$9.74M$9.74M$9.61M$9.42M$10.79M
Inventory$6.50M$5.70M$7.01M$7.77M$7.98M$6.21M$5.80M$6.33M
Current assets$101.47M$101.44M$106.51M$112.73M$113.59M$119.43M$126.91M$139.77M
PP&E, net$1.71M$1.67M$1.62M$1.61M$1.54M$1.46M$1.49M$1.58M
Total assets$104.95M$104.87M$109.70M$115.30M$116.26M$121.97M$129.68M$142.84M
Current liabilities$20.14M$20.50M$18.16M$11.03M$11.83M$11.94M$12.12M$15.47M
Short-term debt$6.06M$10.13M$3.80M$0$0$0$0$0
Long-term debt$34.97M$30.64M$42.38M$40.30M$40.07M$39.82M$39.58M$39.36M
Total debt$41.03M$40.78M$46.18M$40.30M$40.07M$39.82M$39.58M$39.36M
Total liabilities$55.81M$51.98M$55.80M$51.36M$51.97M$51.96M$52.05M$55.32M
Shareholders' equity$49.14M$52.89M$53.90M$63.94M$64.29M$70.01M$77.63M$87.52M
Net debt-$36.37M-$38.98M-$38.78M-$51.66M-$52.30M-$61.68M-$69.19M-$81.00M
Shares outstanding55.22M54.72M54.03M53.49M52.47M52.03M51.38M50.94M
Cash flow statement
Operating cash flow-$2.40M-$5.66M-$7.03M-$1.83M-$8.72M-$7.54M-$11.61M-$3.46M
Capital expenditure$68,000$19,000$60,000-$156,000$170,000$210,000$0$137,000
Free cash flow-$2.47M-$5.68M-$7.09M-$1.67M-$8.89M-$7.75M-$11.61M-$3.60M
Investing cash flow-$68,000-$19,000-$60,000$156,000-$170,000-$210,000$0-$137,000
Financing cash flow$119,000$474,000$88,000$1.26M$25,000$485,000$16,000$5.39M
Depreciation & amortization$100,000$100,000$103,000$108,000$100,000$100,000$149,000$176,000
Stock-based compensation$2.94M$2.96M$2.85M$2.55M$2.42M$3.84M$4.24M$3.95M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.